Biotheus Inc.
Clinical trials sponsored by Biotheus Inc., explained in plain language.
-
Can an immunotherapy drug boost chemotherapy's power against a tough breast cancer?
Disease control OngoingThis phase 3 trial is testing whether adding an experimental immunotherapy drug called PM8002 to standard chemotherapy (nab-paclitaxel) can help people with advanced triple-negative breast cancer live longer without their disease worsening. The study enrolls women aged 18 to 70 w…
Phase: PHASE3 • Sponsor: Biotheus Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers
Disease control OngoingThis phase II trial tests a new drug called PM8002, a bispecific antibody that targets two proteins (PD-L1 and VEGF) involved in tumor growth and immune evasion. It is given together with standard chemotherapy (FOLFIRI) to people with advanced neuroendocrine tumors that have wors…
Phase: PHASE2 • Sponsor: Biotheus Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for tough lung cancer: Dual-Action drug combo in final testing
Disease control OngoingThis phase 3 trial tests a new drug called PM8002, which targets the immune system and tumor blood vessels, combined with the chemotherapy paclitaxel. It is for people with small cell lung cancer whose disease has worsened after initial treatment. The study involves 404 participa…
Phase: PHASE3 • Sponsor: Biotheus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC